Literature DB >> 22321213

Effect of alkyl chain length on sphingosine kinase 2 selectivity.

Kenneth Knott1, Yugesh Kharel, Mithun R Raje, Kevin R Lynch, Webster L Santos.   

Abstract

The conversion of sphingosine to sphingosine-1-phosphate is catalyzed by sphingosine kinase (SphK), which has been implicated in disease states such as cancer and fibrosis. Because SphK exists as two different isoforms, SphK1 and SphK2, understanding the physiological function of each isoenzyme is important. Of the two isoenzymes, SphK2 is significantly less understood, which is evident by the lack of selective small molecule inhibitors. Building on our initial work that focused on the structure-activity relationship study on an FTY720-derived cylohexylamine scaffold, we report that varying the alkyl chain length on the hydrophobic tail can impart selectivity toward SphK2 over SphK1.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321213      PMCID: PMC3394931          DOI: 10.1016/j.bmcl.2012.01.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.

Authors:  Mithun R Raje; Kenneth Knott; Yugesh Kharel; Philippe Bissel; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem       Date:  2011-11-15       Impact factor: 3.641

2.  Synthesis of novel N-protected hydrophobic phenylalanines and their application in potential antibacterials.

Authors:  Timothy P Boyle; John B Bremner; Jonathan A Coates; John Deadman; Paul A Keller; Stephen G Pyne; Kittiya Somphol
Journal:  Eur J Med Chem       Date:  2008-07-09       Impact factor: 6.514

3.  Role of sphingosine kinase 2 in cell migration toward epidermal growth factor.

Authors:  Nitai C Hait; Sukumar Sarkar; Hervé Le Stunff; Aki Mikami; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2005-06-10       Impact factor: 5.157

4.  Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration.

Authors:  Peng Gao; Charles D Smith
Journal:  Mol Cancer Res       Date:  2011-09-06       Impact factor: 5.852

5.  Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines.

Authors:  James R Van Brocklyn; Catherine A Jackson; Dennis K Pearl; Mark S Kotur; Pamela J Snyder; Thomas W Prior
Journal:  J Neuropathol Exp Neurol       Date:  2005-08       Impact factor: 3.685

6.  Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis.

Authors:  Hong Liu; Rachelle E Toman; Sravan K Goparaju; Michael Maceyka; Victor E Nava; Heidi Sankala; Shawn G Payne; Meryem Bektas; Isao Ishii; Jerold Chun; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2003-06-30       Impact factor: 5.157

7.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

9.  Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin.

Authors:  Heidi M Sankala; Nitai C Hait; Steven W Paugh; Dai Shida; Sandrine Lépine; Lynne W Elmore; Paul Dent; Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

10.  Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.

Authors:  Nitai C Hait; Jeremy Allegood; Michael Maceyka; Graham M Strub; Kuzhuvelil B Harikumar; Sandeep K Singh; Cheng Luo; Ronen Marmorstein; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel
Journal:  Science       Date:  2009-09-04       Impact factor: 47.728

View more
  10 in total

1.  Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.

Authors:  Elizabeth S Childress; Yugesh Kharel; Anne M Brown; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  J Med Chem       Date:  2017-04-25       Impact factor: 7.446

2.  Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.

Authors:  Neeraj N Patwardhan; Emily A Morris; Yugesh Kharel; Mithun R Raje; Ming Gao; Jose L Tomsig; Kevin R Lynch; Webster L Santos
Journal:  J Med Chem       Date:  2015-02-13       Impact factor: 7.446

Review 3.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

4.  Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.

Authors:  Molly D Congdon; Yugesh Kharel; Anne M Brown; Stephanie N Lewis; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  ACS Med Chem Lett       Date:  2016-02-02       Impact factor: 4.345

5.  Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.

Authors:  Molly D Congdon; Elizabeth S Childress; Neeraj N Patwardhan; James Gumkowski; Emily A Morris; Yugesh Kharel; Kevin R Lynch; Webster L Santos
Journal:  Bioorg Med Chem Lett       Date:  2015-03-23       Impact factor: 2.823

6.  Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles.

Authors:  Joseph D Houck; Thomas K Dawson; Andrew J Kennedy; Yugesh Kharel; Niels D Naimon; Saundra D Field; Kevin R Lynch; Timothy L Macdonald
Journal:  ACS Med Chem Lett       Date:  2016-03-01       Impact factor: 4.345

7.  Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors.

Authors:  Molly Congdon; Russell G Fritzemeier; Yugesh Kharel; Anne M Brown; Vlad Serbulea; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  Eur J Med Chem       Date:  2020-12-29       Impact factor: 6.514

Review 8.  The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Authors:  Sathya Narayanan Patmanathan; Lee Fah Yap; Paul G Murray; Ian C Paterson
Journal:  J Cell Mol Med       Date:  2015-07-14       Impact factor: 5.310

9.  Structure-activity relationships and molecular modeling of sphingosine kinase inhibitors.

Authors:  Dong Jae Baek; Neil MacRitchie; Nahoum G Anthony; Simon P Mackay; Susan Pyne; Nigel J Pyne; Robert Bittman
Journal:  J Med Chem       Date:  2013-11-14       Impact factor: 7.446

10.  The impact of sphingosine kinase inhibitor-loaded nanoparticles on bioelectrical and biomechanical properties of cancer cells.

Authors:  Hesam Babahosseini; Vaishnavi Srinivasaraghavan; Zongmin Zhao; Frank Gillam; Elizabeth Childress; Jeannine S Strobl; Webster L Santos; Chenming Zhang; Masoud Agah
Journal:  Lab Chip       Date:  2015-11-26       Impact factor: 6.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.